These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 17028247)

  • 1. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
    Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
    Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
    Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
    Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
    Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
    Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas.
    Tachibana T; Onodera H; Tsuruyama T; Mori A; Nagayama S; Hiai H; Imamura M
    Clin Cancer Res; 2005 Oct; 11(20):7322-7. PubMed ID: 16243803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.
    Rogers PR; Matsumoto A; Naidenko O; Kronenberg M; Mikayama T; Kato S
    J Immunol Methods; 2004 Feb; 285(2):197-214. PubMed ID: 14980434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation.
    Haraguchi K; Takahashi T; Hiruma K; Kanda Y; Tanaka Y; Ogawa S; Chiba S; Miura O; Sakamaki H; Hirai H
    Bone Marrow Transplant; 2004 Oct; 34(7):595-602. PubMed ID: 15300228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
    Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
    Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
    Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
    Osada T; Morse MA; Lyerly HK; Clay TM
    Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
    Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
    Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
    Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.
    Motohashi S; Kobayashi S; Ito T; Magara KK; Mikuni O; Kamada N; Iizasa T; Nakayama T; Fujisawa T; Taniguchi M
    Int J Cancer; 2002 Nov; 102(2):159-65. PubMed ID: 12385012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.